| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
821 |
722 |
$37K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
613 |
538 |
$31K |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
540 |
482 |
$16K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
382 |
350 |
$16K |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
295 |
246 |
$12K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
167 |
148 |
$10K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
107 |
94 |
$8K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
110 |
109 |
$8K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
60 |
43 |
$6K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
79 |
77 |
$3K |
| 87634 |
|
47 |
45 |
$2K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
30 |
30 |
$1K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
16 |
15 |
$909.60 |
| U0001 |
Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel |
15 |
12 |
$538.65 |
| 0011A |
|
12 |
12 |
$401.94 |
| 81002 |
|
27 |
15 |
$70.20 |
| 99072 |
|
186 |
118 |
$56.25 |
| 99051 |
|
110 |
74 |
$0.00 |